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Aims: Few studies have assessed the effects of cell therapy in non-ischemic 
cardiomyopathies which, however, contribute to a large number of cardiac failures. 
Assuming that such conditions are best suited for a global delivery of cells, we assessed 
the effects of epicardially-delivered adipose tissue-derived stroma cell (ADSC) 
sheets in a mouse model of dilated cardiomyopathy based on cardiac-specifi c and 
tamoxifen-inducible invalidation of serum response factor.
Methods and Results: Three weeks after tamoxifen administration, the function 
of the left ventricle (LV) was assessed by echocardiography. Twenty-nine mice were 
then allocated to control (n=9, non-transgenic), sham (n=10, transgenic non-treated) 
and treated (n=10, transgenic) groups. In the treated group, 3x106 allogeneic ADSCs 
were cultured for 2 days onto temperature-responsive polymers and the generated 
sheets were then transplanted over the surface of the heart. In 10 additional mice, 
the sheet was made of GFP-labeled ADSCs to track cell fate. Function, engraftment, 
and fi brosis were blindly assessed after 3 weeks. In the non-treated group, fractional 
shortening declined compared with baseline whereas the sheet application resulted 
in its stabilization. This correlated with a lesser degree of LV remodeling, as LV 
end-diastolic and end-systolic diameters did not differ from baseline values. Many GFP+ 
cells were identifi ed in the epicardial graft and in the myocardium. Treated animals 
also displayed a reduced expression of the stress-induced atrial natriuretic factor and 
beta-myosin heavy chain genes. These protective effects were also accompanied by 
a reduction of myocardial fi brosis.
Conclusion: These results strongly suggest the functional relevance of epicardially-
delivered cell-seeded biomaterials to non-ischemic heart failure.
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AggreWell plate aggregation and defi ned factors allow highly uniform-sized 
and functional cardiac embryoid bodies from human ESCs and iPSCs
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Differentiation of hESCs and hiPSCs to the cardiac lineage can be done using 
different methods: co-culture with mouse visceral endoderm-like cells (END-2 cells), 
through formation of embryoid bodies (EBs) or culturing as a monolayer on matrigel 
supplemented with defi ned factors. In this study, we present cardiac differentiation 
of hESCs and hiPSCs by formation of EBs through forced aggregation of the cells.
From hESC and hiPSC cells plated on matrigel, EBs are formed by forced 
aggregation in AggreWell plates with±2000 cells per EB. The differentiation process 
is achieved using defi ned growth factors (Activin A, BMP4, VEGF, IWR1 and FGF2) 
at different stages as previously shown to enhance mesodermal differentiation and 
cardiac progenitors. qPCR and immunocytochemistry are performed to evaluate the 
gene and protein profi le while atomic force microscopy (AFM) and calcium release 
are used to investigate the functional cardiac properties.
The forced aggregation using AggreWell plates allows highly uniform-sized EBs 
with up to 50% of contracting clusters. Our hESC-CMs and hiPSC-CMs expressed 
cardiac specifi c markers such as cardiac troponin T and cardiac ryanodine receptor 
/ calcium release channel (RyR2). Our hESC-CMs are able to respond to activation 
(isoproterenol) as well as to inhibition (metoprolol) of beta-adrenergic receptors. We 
use the AFM technique to quantify the contractile and elastic properties of the cardiac 
EBs. To assess the functionality of the sarcoplasmic reticulum, calcium events are 
investigated using fl uorescent microscope. Exposure of enzymatically-dissociated 
hESC-CMs to caffeine, a RyR2 agonist, induces a quick and large calcium wave 
followed by a long and total absence of calcium transient. These results suggest that 
the EBs contained functional human cardiomyocytes.
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The brain natriuretic peptide increases the number of cardiac precursors 
and newly formed cardiomyocytes in vitro and in vivo: a new therapeutic 
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Brain natriuretic peptide (BNP) is a well known cardiac hormone, secreted mainly 
by cardiomyocytes, whose effects on the regulation of natriuresis, diuresis and vascular 
tone are well documented. Although its role in the heart itself is not elucidated, BNP 
treatment preserves cardiac tissue and improves cardiac function when administered 
either before or after myocardial ischemia in animals models. This protective role 
has been attributed to fi brosis inhibition, as well as reduction of cardiomyocyte’s 
apoptosis and hypertrophy. 
In this study, we investigated whether part of this protection afforded by BNP 
is due to an effect on the proliferation and/or differentiation into cardiomyocytes of 
cardiac precursor cells (CPCs).
In a fi rst step, we determined by immunostainings that CPCs, whether examined 
in vivo in neonatal and adult hearts or in vitro during cell differentiation into cardio-
myocytes, expressed the NPR-A and NPR-B receptors. In a second step, neonatal 
non-myocyte cells (NMCs), a mixed cell population comprising the CPCs, were 
cultured with or without BNP (5 μg/mL). BNP treatment of these cells increased the 
number of CPCs and their differentiation into cardiomyocytes when compared to 
culture conditions without BNP. 
In parallel, we injected BNP to 2-3 days-old pups and to adult mice (10 weeks 
old). The effect of the BNP injection on the heart of these animals was evaluated by 
echocardiography (cardiac function) and immunostainings (protein expression). The 
cardiac functions of BNP injected mice were not altered. However, a higher number 
of CPCs and newly formed cardiomyocytes (Nkx2.5+ laminin+) was detected in the 
heart of neonatal and adult BNP injected mice compared to non-injected mice. 
These results support a key role for BNP in controlling the CPC fate in neonatal 
and adult hearts. BNP appears thus to be an essential factor to induce cardiac cell 
regeneration following cardiac damages.
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A new microRNA regulates insulin signalling pathway in vascular smooth 
muscle cells and may be implicated in insulin-resistance and diabetes
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Many of the complications of diabetes are of vascular origin. It is now established 
that insulin like other growth factors regulates normal vessel homeostasis and abnormal 
arterial growth that occurs in vascular disease. In particular insulin induces proliferation 
of vascular smooth muscle cells (VS MC). 
We identifi ed a new microRNA, miR-X, which is upregulated after a prolonged 
stimulation with insulin. Interestingly this microRNA was predicted to target several 
members of the insulin signaling pathway like INSR (insulin receptor), IGF1R (IGF-1 
receptor) and MAP2K1 (MEK1) and pro-proliferative CCND1 (cyclin D1). Our 
hypothesis is that miR-X by targeting the insulin pathway may play a role in insulin 
resistance and its cardiovascular consequences. miR-X overexpression inhibited VS 
MC proliferation induced by insulin. Moreover INSR, IGF1R, MEK2 and cyclin 
D1 proteins were signifi cantly decreased by miR-X overexpression. Our data also 
confi rmed that miR-X directly targets INSR, IGF1R and cyclin D1 mRNA in VS 
MC. In addition the induction of AKT phosphorylation by insulin was signifi cantly 
decreased in miR-X overexpressing VS MC as well as glucose incorporation. All 
these fi ndings point towards a role of miR-X as a regulator of insulin signaling in 
VS MC. Furthermore miR-X is expressed in many tissues and we found that miR-X 
expression is altered in the liver and muscle of Goto-kakizaki rats and in the liver of 
high fat diet mice. We now want 1) to modulate its expression in mice and study the 
consequences of its deregulation on insulin resistance and 2) to search if its expression 
is altered in the serum of human diabetic patients.
